



Palliating chronic breathlessness

Miriam Johnson

Wolfson Palliative Care Research Centre University of Hull









Content

- Chronic breathlessness definition
- Management
 - Non-pharmacological
 - Pharmacological
- ➤ Any questions?

Quality of life and the impact of chronic breathlessness (whole adult population)






Currow D et al. Thorax 2017. 72; 1151-1153

The impacts of persisting breathlessness on workforce participation in people of working age

Percentage of people participating in the paid workforce by level of chronic breathlessness (n=6064) from a randomly selected cross-section of the population aged 20-65.




Face-to-face interviews in people's own home.

Data from three years ('06, '15, '17).

Analysis limited to people of working age.

Persisting breathlessness and health service utilisation

Health service contact by level of persisting breathlessness in a random sample of the



mMRC – modified Medical Research Council breathlessness scale; GP – general practitioner; ED – emergency department

Currow DC et al. ERJ Open Res 2021;7(4):00415-2021.


Not noticed...

Ahmadi Z et al ERJ 2018


- 59 years old, severe COPD former smoker,
- + triple inhalation therapy,
 'flu/pneumococcus vaccine
- individualised pulmonary rehabilitation
- At follow-up, severe
 ["breathlessness" or "pain"] that
 markedly restricted daily
 activities, unchanged for at least
 three months.
- Taking paracetamol/ NSAID allergy

Questions to respiratory physicians

- 1. Needs further treatment?
- 2. What type of treatment?







Management of chronic breathlessness

Chronic is different: central processing

- The brain creates expectations and beliefs (psychological "priors") based on previous experience which influence incoming breathlessness sensations . Faull O et al Cortex 2017
- People living with chronic breathlessness process the sensation of breathlessness involving the frontal association cortex; in the context of memory and fear associated with past experiences. Healthy volunteers do not. Herigstad M et al Chest 2015
- Interventions such as pulmonary rehabilitation, which aim to educate and change such beliefs, also show corresponding reduction in fMRI frontal association cortex activity. Herigstad M et al Eur Respir J 2017
- Opioids suppress conditioned anticipatory brain responses to breathlessness Hayen A, et al Neuroimage 2017

Managing breathlessness: general principles - a *complex intervention*

1. Non pharmacological measures

- 2. Morphine
- 3. Oxygen not for palliation of breathlessness
- 4. Other drugs e.g. antidepressants
- 5. Manage other symptoms
- Remember the carers!

Evidence based – complex interventions

Pulmonary rehabilitation

- McCarthy B et al. Cochrane Database of Systematic Reviews 2015, Issue 2.
 Art. No.: CD003793.
- Spruit MA et al. Am J Respir Crit Care Med 2013 Oct 15;188(8):e13-e64.

Cardiac rehabilitation

- O'Connor CM et al. JAMA 2009; 301(14):1439-1450
- McMurray JJ et al. Eur J Heart Fail 2012; 14(8):803-869

Generic rehabilitation

Evans RA et al. Respir Med 2010 Oct;104(10):1473-81

Breathlessness intervention services

• Bausewein C et al Chron Resp Dis 2018, 15 (1): 48-59

Inefficient breathing Increased work of breathing

Attention to the sensation
Memories of past experiences
Misconceptions and thoughts
about dying

Breathing

Increased respiratory rate
Inappropriate accessory muscle use
Dynamic hyperinflation



Thinking

Anxiety, feelings of panic Frustration, anger, low mood

Functioning

Cardiovascular and muscular deconditioning

Reduced activity Social isolation Reliance on help

> Clinician version May 17

BREATHING: Airflow relieves chronic breathlessness in people with advanced disease: an exploratory systematic review and meta-analyses.

Swan F et al 2019 Palliative Medicine


Results

16/78 studies (n=929) 11 RCTs oxygen vs medical air, 4 RCTs of fan vs control 1 fan cohort study.

Fan at rest (variety of diagnoses) –

2. Airflow delivered as cylinder medical air at rest (advanced cancer)

3. Airflow delivered as cylinder medical air during a constant load exercise test (COPD completing pulmonary rehabilitation)



Breathing

Hand-held fan

- Mixed methods analysis of pooled qualitative data (n=133): 82% perceived some/substantial benefit (Luckett T et al 2017)
- Used as part of a complex intervention no further trials of the individual fan component needed (Johnson MJ et al J Pain & Symptom Manage 2016)

Well I used to use Ventolin up to 30 times a day and I don't use it at all now...

I have a much quicker recovery than I used to...

The best things were that it worked, it had a positive effect on my condition. .. now I've resumed cooking...

THINKING

- Understand triggers, context and meaning of breathlessness
- Crisis plans. (Mularski RA et al. An official American Thoracic Society workshop report: assessment and palliative management of dyspnea crisis Ann Am Thorac Soc. 2013)
- Anxiety/panic interventions
- Cognitive behavioural therapy (Howard C, Dupont S. The COPD breathlessness manual...in patients with chronic obstructive pulmonary disease. NPJ Prim Care Respir Med 2014; 24:14076.)

FUNCTIONING

Adaptive

- Exercise and activity encouraged
- Maintain social contact
- Self-efficacy
- Modify/maintain role


Maladaptive

- Restrict activity
- Social isolation
- Helplessness
- Receipt of help
- Reduced role
- ➤ Remember the carer. Involve them in education about, and practice with the interventions.
- ➤ Key role for clinician: where address breathlessness in addition to disease = maximise Breathing Space (Hutchinson A et al Eur Resp J 2017)

Breathlessness ladder

- First step
 - ✓ Optimise treatment of the underlying disease
 - Second step
 - ✓ Non-pharmacological measures (pulmonary rehabilitation; exercise; cognitive behavioural therapy; fan; pacing/prioritising; anxiety management; relaxation; pursed lip breathing; diaphragmatic breathing)
 - ✓ Education and support for family carers
 - ✓ Crisis plan
 - Third step
 - ✓ <u>Consider</u> low dose sustained release oral morphine (NB remember laxatives and manage side-effects; judging increased exercise tolerance)






Pharmacological interventions

ERS statement – non-malignant disease 2024

- We suggest not using opioids for the treatment of breathlessness in people with serious respiratory illness (conditional recommendation against the intervention, very low certainty of evidence).
 - However, when clinicians are considering prescribing opioids ...clear communication and shared decision making between clinicians and patients are required considering:
 - benefits and harms, and active discussion and plans to manage side effects.
 - patients' goals and willingness to use an opioid medication,
 - their understanding of how to take the medication correctly, and the broader impacts on their lives (including the ability to drive) and other potential harms.
 - clinicians and the patients' informal caregivers may require education and support regarding the use of opioids

Opioids and central modulation

- Breathlessness perception is processed in brain areas rich in opioid receptors.
 - von Leupoldt A., et al. Neuroimage 2009; 48(1):200-206.
 - Reeves KC et al. Front. Mol. Neurosci 2022; 15: https://doi.org/10.3389/fnmol.2022.919773
- Endogenous opioids reduce breathlessness, the opioid antagonist, naloxone, increases exertion-induced breathlessness.
 - Gifford AH, et al. COPD 2011; 8(3):160-166.
 - Mahler DA, et al. Eur Respir J 2009; 33(4):771-777.




fMRI studies

- Remifentanil reduces the sensation, "urge to breath"
 - Pattinson KT, et al. J Neurosci 2009; 29(25):8177-8186.
- The brain creates expectations and beliefs (psychological "priors") which then influence the perception of incoming breathlessness sensations; Faull OK, et al Cortex 2017; 95:211-221.
- Opioids suppress conditioned anticipatory brain responses to breathlessness; Hayen A, et al Neuroimage 2017
- In people with chronic breathlessness (using morphine) and healthy volunteers (remifentanil), worse mood reduces breathlessness response to opioids: as depression and anxiety increases, so opioid responsiveness decreases; Abdallah SJ,et al. Eur Respir J 2019; 54(3).

Summary basic science

- Endogenous opioids modify perception of breathlessness
- Evidence for a central modulation is the dominant feature
- Opioids reduce the sensation "urge to breathe" through central mechanisms
- The response to opioids is reduced by impaired affect (anxiety, depression)
- Opioids appear to be able to modulate anticipatory breathlessness as well as the sensation of breathlessness itself







Why look at laboratory and daily life trials separately?

Systematic review and meta-analysis - all diagnoses

Ekstrom M et al. Thorax 2017







Laboratory evidence of exogenous opioids

Laboratory studies measuring breathlessness at iso-time or iso-load

Study or Subgroup	Std. Mean Difference	SE	Weight	Std. Mean Difference IV, Random, 95% CI	Std. Mean Difference IV, Random, 95% CI
Abdallah 2017 (1)	-0.5448	0.3227	28.5%	-0.54 [-1.18, 0.09]	-
Johnson 1983 (2)	-0.4172		26.0%	-0.42 [-1.08, 0.24]	-
Light 1989 (3)	-0.6276	0.4035	18.2%	-0.63 [-1.42, 0.16]	
Light 1996 (4)	-0.5327	0.5476	9.9%	-0.53 [-1.61, 0.54]	
Woodcock 1981 (5)	-0.3901	0.4129	17.4%	-0.39 [-1.20, 0.42]	
Total (95% CI)			100.0%	-0.50 [-0.84, -0.16]	•
Heterogeneity: Tau ² = Test for overall effect:	0.00; Chi² = 0.25, df = 4	(P = 0.99	3); I² = 0%	_	-2 -1 0 1 2
restroi overali ellect.	2-2.30 (1 - 0.004)				Favours opioids Favours placebo

Holland AE, et al. European Respiratory Society Clinical Practice Guideline; ERJ 2024

Opioids - outcome exercise endurance - improved with opioids; Lui et al Pall Med J 2023

	0/ 1 14 - 15//	~=		Std. Mean Difference	Std. Mean Difference
	Std. Mean Difference	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
1.3.1 Cross-over stud	dies				
Abdallah 2017	0.45	0.15	7.7%	0.45 [0.16, 0.74]	
Beauford 1993	0.72	0.56	2.0%	0.72 [-0.38, 1.82]	
Eiser-1 1991	0.09	0.19	6.8%	0.09 [-0.28, 0.46]	
Eiser-2 1991	0.15	0.21	6.4%	0.15 [-0.26, 0.56]	
Jankelson 1997	-0.12	0.15	7.7%	-0.12 [-0.41, 0.17]	-
Jensen 2012	0.59	0.2	6.6%	0.59 [0.20, 0.98]	
Johnson 1983	0.27	0.09	9.0%	0.27 [0.09, 0.45]	-
Leung 1996	0.11	0.2	6.6%	0.11 [-0.28, 0.50]	-
Light-1 1996	0.2	0.54	2.1%	0.20 [-0.86, 1.26]	-
Light 1989	0.5	0.12	8.4%	0.50 [0.26, 0.74]	_
Light-2 1996	1.04	0.59	1.8%	1.04 [-0.12, 2.20]	1
Masood 1995	-0.63	0.19	6.8%	-0.63 [-1.00, -0.26]	
Poole 1998	-0.85	0.44	2.9%	-0.85 [-1.71, 0.01]	
Woodcock 1981	1.24	0.54	2.1%	1.24 [0.18, 2.30]	
Woodock 1982	0.27	0.18	7.0%	0.27 [-0.08, 0.62]	1
Young 1989	0.62	0.47	2.6%	0.62 [-0.30, 1.54]	1.
Subtotal (95% CI)			86.6%	0.22 [0.02, 0.41]	•
Heterogeneity: Tau ² =	0.09; Chi ² = 50.54, df = 1	5 (P <	0.00001);	l ² = 70%	
Test for overall effect:		•	,,		


Summary laboratory studies

- opioids reduce breathlessness
- opioids increase exercise endurance

when measured at isotime or with isoload

 There is a strong relationship between breathlessness and physical and emotional exertion





Daily life trials

Pragmatic studies measuring breathlessness during 'daily life'


			•	Placebo		Std. Mean Difference		Std. Mean Differ		
Study or Subgroup	Std. Mean Difference	SE	Total	Total	Weight	IV, Random, 95% CI		IV, Random, 95	% CI	
Abernethy 2003 (1)	-0.4043	0.2319	38	38	10.5%	-0.40 [-0.86, 0.05]				
Currow 2020 (2)	-0.0665	0.1187	145	139	11.1%	-0.07 [-0.30, 0.17]		*		
Ekstrom 2022 (3)	0.0619	0.1991	51	50	10.7%	0.06 [-0.33, 0.45]		+		
Ferreira 2018 (4)	0.3125	0.3266	19	19	9.8%	0.31 [-0.33, 0.95]		+•		
Ferreira 2020 (5)	1.9064	0.1947	74	81	10.8%	1.91 [1.52, 2.29]			-	
Johnson 1983 (6)	-0.444	0.3379	18	18	9.7%	-0.44 [-1.11, 0.22]				
Kronborg-White 2020 (7)	-1.4998	0.3824	18	18	9.3%	-1.50 [-2.25, -0.75]	-			
Poole 1998 (8)	-0.457	0.3837	14	14	9.3%	-0.46 [-1.21, 0.30]				
Rice 1987 (9)	-0.5508	0.5484	7	7	7.8%	-0.55 [-1.63, 0.52]				
Verberkt 2020 (10)	-0.2335	0.1906	54	57	10.8%	-0.23 [-0.61, 0.14]				
Total (95% CI)			438	441	100.0%	-0.10 [-0.64, 0.44]		•		
Heterogeneity: Tau² = 0.67;	Chi² = 119.85, df = 9 (P	< 0.0000	01); I² = 92	2%			-4	 	1	$\overline{}$
Test for overall effect: $Z = 0$.	.37 (P = 0.71)						Favo	urs opioids Favo	urs placebo	7

Holland AE, et al. European Respiratory Society Clinical Practice Guideline; ERJ 2024

Messages?

- No evidence of benefit for breathlessness perception
- However, consistent signal of benefit in those with more severe breathlessness
- mixed findings with the few that had an activity component but,
 - Used non-isotime and self-regulated test such as 6MWT, or average daily steps, so exercise endurance benefit can be missed
 - Signal of benefit seen with some 6MWTs, or more detailed analysis of actigraphy (beyond the average daily steps)

Ferreira et al BEAMS substudy ERJ 2022






Figure 1 – Arm differences in mean activity calories (left) and mean minutes lightly active (right) from baseline to the end of week 3. (FitBIT measures)

Signal of benefit in mean active calories at 3 weeks. In morphine groups



MABEL trial

Primary outcome

Secondary outcomes

Physical activity

Cough


Measure	Day	Adjusted mean difference (95% confidence intervals)	p value	
Worst breathlessness (NRS 0- 10)	28	0.09 (-0.57, 0.75)	0.781	
	56	-0.26 (-0.93, 0.42)	0.453	
	Overall effect	-0.20 (-0.60, 0.20)	0.322	
Levels of physical activity (minutes/day)	28			
sedentary	1	-21.4 (-78.1, 35.30)	0.456	
light		11.96 (-17.4, 41.34)	0.421	
moderate/vigorous		9.51 <u>(0.54</u> , 18.48)	0.038	
Cough (NRS 0-10)	28	-0.36 (-1.11, 0.40)	0.353	
	56	-1.41 (-2.18, -0.64)	<0.001	
	Overall effect	-0.70 (-1.22, -0.17)	0.009	

Probability of cost-effectiveness at £20,000 NICE thresholds = 65% at Day 28 Scenario based analysis excluding non-related SAEs = 88% at Day 28

MABEL trial - so what?

- Consistent with other 'daily life' trials without an isotime/load measure of breathlessness
- Further <u>supports</u> evidence of better exercise endurance
- Further <u>supports</u> evidence of benefit for cough
- Small QoL improvements, but enough to give a favourable health economic evaluation (assuming attribution is correct)
- Dose regimen (start at 5mg MST BD) with close monitoring and early management of expected sideeffects gives better tolerability






Safety

Safety

- Trials to date side-effects mild, expected and self-limiting mainly during the 1st week – but ongoing monitoring is necessary, ...
- Morphine has a known safety profile and should be prescribed i) for the right patient, ii) with due care in monitoring; same for beta blockers, ACE-inhibitors, beta agonists, anti-diabetic medication, digoxin, ...
- Beware constipation breathlessness could get worse...
- Don't assume non-palliative care clinicians know how to initiate or monitor opioids
- Common sense care re driving (awaiting BEAMS subgroup study findings)
- Beware fluctuating renal function (morphine)





SUMMARY

VERDICT

- Do opioids improve breathlessness and exercise endurance in laboratory trials? YES
- Do opioids improve breathlessness <u>at rest</u> in clinical study?
 YES (Abernethy et al)
- Do opioids improve <u>exercise endurance in ambulant people</u> with moderate to severe breathlessness? <u>MAYBE</u>
- How to capture benefit in those who are ambulant and comfortable at rest?
 - Once physical exertion starts to complicate the situation, a primary measure of breathlessness may be less helpful
 - Unless breathless at rest, need a standardized exercise endurance test
- THE MORPHINE STORY IS NOT FINISHED YET....



Thank you

miriam.johnson@hyms.ac.uk

https://www.hyms.ac.uk/research/research-centresand-groups/wolfson/breathlessness/bringingbreathlessness-into-view-exhibition





